Synthego
Redwood City, US · Founded 2012 · Delaware corporation · 13 known investors
Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
Synthego was founded in 2012 by Paul John Dabrowski and Michael Jakub Dabrowski.
PJ
Paul John DabrowskiCo-founder
MJ
Michael Jakub DabrowskiCo-founder
Board
DO
SN
Investors · 13
AAF Management Ltd.Washington
AME Cloud VenturesPalo Alto · $1M – $10M
Declaration PartnersNew York
Founders FundSan Francisco · $500K – $5Mvia Scott Nolan · board
Khosla VenturesMenlo Park · $5K – $50M
Menlo VenturesSan Francisco · $1M – $20M
Open Field CapitalNew York
Perot JainDallas · $500K
SoftBank Vision FundLondon
8VCreported · 2 sourcesAustin · $100K – $50M
Intel CapitalreportedSanta Clara · $1M – $20M
OS Fundreported · 2 sourcesPark Ridge · $1M – $2M
RA CapitalreportedBoston
Reported raises · per SEC filings
Form D private placements$147M disclosed across 2 rounds · 2016–2018
▶$106.3MraisedOct 2018 · 29 investors · BiotechnologyRule 506(b)
▶$106.3MraisedOct 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Drew OettingDirector
- Scott NolanDirector
- Michael Jakub DabrowskiExecutive Officer, Director
- Forrest Baringer-JonesExecutive Officer
- Paul John DabrowskiExecutive Officer, Director
- Offering amount
- $116.3M
- Amount sold
- $106.3M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.7MraisedJan 2017 · 22 investors · BiotechnologyRule 506(b)
▶$40.7MraisedJan 2017 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul John DabrowskiExecutive Officer, Director
- Michael Jakub DabrowskiExecutive Officer, Director
- Drew OettingDirector
- Scott NolanDirector
- Offering amount
- $40.7M
- Amount sold
- $40.7M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Synthego went on to found or lead other companies.
Competitors · 2
by search overlapCRISPR878 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
Read on Scientific American755 shared keywordsScientific American is a science and technology news publication covering research, discoveries, and developments across fields such as astronomy, biology, physics, health, and climate. It publishes articles, magazine issues, discussions, and organizes reader travel experiences and editorial features.
Companies competing with Synthego for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Synthego do?
- Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
- Who founded Synthego?
- Synthego was founded by Paul John Dabrowski, Michael Jakub Dabrowski in 2012.
- Who are Synthego's investors?
- Synthego's investors include AAF Management Ltd., AME Cloud Ventures, Declaration Partners, Founders Fund, Khosla Ventures, Menlo Ventures, Open Field Capital, Perot Jain and 5 more.
- How much funding has Synthego raised?
- Synthego has disclosed $147M raised across 2 rounds.
- Where is Synthego headquartered?
- Synthego is headquartered in Redwood City, US.